BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20928937)

  • 1. Hedgehog pathway activation in chronic myeloid leukemia.
    Jagani Z; Dorsch M; Warmuth M
    Cell Cycle; 2010 Sep; 9(17):3449-56. PubMed ID: 20928937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of the signal transducer Smo links microRNA-326 to the oncogenic Hedgehog pathway in CD34+ CML stem/progenitor cells.
    Babashah S; Sadeghizadeh M; Hajifathali A; Tavirani MR; Zomorod MS; Ghadiani M; Soleimani M
    Int J Cancer; 2013 Aug; 133(3):579-89. PubMed ID: 23341351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia.
    Irvine DA; Zhang B; Kinstrie R; Tarafdar A; Morrison H; Campbell VL; Moka HA; Ho Y; Nixon C; Manley PW; Wheadon H; Goodlad JR; Holyoake TL; Bhatia R; Copland M
    Sci Rep; 2016 May; 6():25476. PubMed ID: 27157927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Acylguanidine Derivatives Targeting Smoothened Induce Antiproliferative and Pro-Apoptotic Effects in Chronic Myeloid Leukemia Cells.
    Chiarenza A; Manetti F; Petricci E; Ruat M; Naldini A; Taddei M; Carraro F
    PLoS One; 2016; 11(3):e0149919. PubMed ID: 26934052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation.
    Dierks C; Beigi R; Guo GR; Zirlik K; Stegert MR; Manley P; Trussell C; Schmitt-Graeff A; Landwerlin K; Veelken H; Warmuth M
    Cancer Cell; 2008 Sep; 14(3):238-49. PubMed ID: 18772113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis.
    Mar BG; Amakye D; Aifantis I; Buonamici S
    Leukemia; 2011 Nov; 25(11):1665-73. PubMed ID: 21660044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis.
    Li H; Liu L; Zhuang J; Liu C; Zhou C; Yang J; Gao C; Liu G; Sun C
    Mol Genet Genomic Med; 2019 Sep; 7(9):e851. PubMed ID: 31373443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia.
    Parting O; Langer S; Kuepper MK; Wessling C; Li S; Braunschweig T; Chatain N; Maié T; Costa IG; Crysandt M; Huber M; Brümmendorf TH; Koschmieder S; Schemionek M
    Leukemia; 2020 Oct; 34(10):2635-2647. PubMed ID: 32684632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
    Brechbiel J; Miller-Moslin K; Adjei AA
    Cancer Treat Rev; 2014 Jul; 40(6):750-9. PubMed ID: 24613036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the Hedgehog pathway in chronic myelogeneous leukemia patients.
    Long B; Zhu H; Zhu C; Liu T; Meng W
    J Exp Clin Cancer Res; 2011 Jan; 30(1):8. PubMed ID: 21235817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia.
    Zhao C; Chen A; Jamieson CH; Fereshteh M; Abrahamsson A; Blum J; Kwon HY; Kim J; Chute JP; Rizzieri D; Munchhof M; VanArsdale T; Beachy PA; Reya T
    Nature; 2009 Apr; 458(7239):776-9. PubMed ID: 19169242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling.
    Agarwal P; Li H; Choi K; Hueneman K; He J; Welner RS; Starczynowski DT; Bhatia R
    Cell Rep; 2021 Jul; 36(2):109386. PubMed ID: 34260914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia.
    Morotti A; Panuzzo C; Fava C; Saglio G
    Expert Opin Biol Ther; 2014 Mar; 14(3):287-99. PubMed ID: 24387320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The one-two punch: combination treatment in chronic myeloid leukemia.
    Sweet KL; Hazlehurst LA; Pinilla-Ibarz J
    Crit Rev Oncol Hematol; 2013 Dec; 88(3):667-79. PubMed ID: 23969231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting BMP signaling in the bone marrow microenvironment of myeloid leukemia.
    Lefort S; Maguer-Satta V
    Biochem Soc Trans; 2020 Apr; 48(2):411-418. PubMed ID: 32167132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
    Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
    Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
    El Eit R; Itani AR; Nassar F; Rasbieh N; Jabbour M; Santina A; Zaatari G; Mahon FX; Bazarbachi A; Nasr R
    Cancer; 2019 Aug; 125(16):2818-2828. PubMed ID: 31034603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.